HC Wainwright began coverage on shares of Vivani Medical (NASDAQ:VANI – Free Report) in a research report sent to investors on Thursday, MarketBeat reports. The firm issued a buy rating and a $3.00 price objective on the stock.
Vivani Medical Price Performance
NASDAQ:VANI opened at $1.26 on Thursday. The stock has a market cap of $69.63 million, a P/E ratio of -2.68 and a beta of 3.20. The business’s 50-day moving average price is $1.22 and its two-hundred day moving average price is $1.37. Vivani Medical has a twelve month low of $0.84 and a twelve month high of $7.80.
Vivani Medical (NASDAQ:VANI – Get Free Report) last announced its earnings results on Tuesday, August 13th. The company reported ($0.10) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.02.
About Vivani Medical
Vivani Medical, Inc, a clinical stage company, develops various implants that treat chronic diseases with high unmet medical need. It engages in developing a portfolio of miniature drug implants to deliver minimally fluctuating drug profiles; and implantable visual prostheses devices to deliver useful artificial vision to blind individuals.
See Also
- Five stocks we like better than Vivani Medical
- How to Invest in Small Cap Stocks
- Airbnb Stock Attracts Attention With Strong Cash Flow Strategy
- Manufacturing Stocks Investing
- MarketBeat Week in Review – 11/4 – 11/8
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Trump’s Return: Which Sectors Will Benefit Most?
Receive News & Ratings for Vivani Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vivani Medical and related companies with MarketBeat.com's FREE daily email newsletter.
